Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Sequencing data is all well and good, but what does it mean?
GE arrives to the spin-out party fashionably late.